UroAlert - GU Oncology Weekly

November 20, 2024

Videos

Peer-to-Peer Clinical Conversations

Five Things Urologists Need to Know About Bladder and Kidney Cancer in 2025 "Presentation" - Gautam Jayram

Gautam Jayram

At the 2024 LUGPA annual meeting, Gautam Jayram discusses key updates in bladder and kidney cancer management.

Challenges in Defining High-Risk Localized Prostate Cancer for Optimal Treatment "Presentation" - Martin Gleave

Martin Gleave

At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Martin Gleave reviews risk stratification challenges in high-risk prostate cancer, highlighting current system limitations.

Beyond the Abstracts

Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis - Beyond the Abstract

Multiplex Imaging of Localized Prostate Tumors Reveals Altered Spatial Organization of AR-Positive Cells in the Microenvironment - Beyond the Abstract

Conference Coverage

ESMO 2024: Similar Genetic Profile in Early and Late Stage Urothelial Tract Cancer Suggests That Early Genomic Testing Bears the Potential of Timely Personalized Treatment in Clinical Trials

ESMO 2024: STAR-EV: Stereotactic Treatment with Neoadjuvant Radiotherapy and Enfortumab Vedotin: A Phase I/II Study for Localized, Cisplatin Ineligible, Muscle Invasive Bladder Cancer

ESMO 2024: Targeting Epigenetic Pathways

ESMO 2024: A Phase II Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Non-Muscle Invasive BCG Unresponsive Urothelial Carcinoma of the Bladder

ESMO 2024: Invited Discussant: CC-94676-PCA-001 and INSPIRE

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

Spectral CT for non-invasive evaluation of bladder cancer grade.

Bladder Sparing Options for Muscle-Invasive Bladder Cancer - Beyond the Abstract

Performance and Clinical Implications of VI-RADS in detecting muscle invasion in bladder tumors: A prospective observational study.

The role of MRI in muscle-invasive bladder cancer: an update from the last two years.

Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.

Guidelines versus real-world data in metastatic bladder cancer: A population-based study on first-line chemotherapy treatment patterns.

Reduced p63 expression is linked to unfavourable prognosis in muscle-invasive urothelial carcinoma of the bladder.

Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study.

"I was in a very deep, dark place... I wasn't prepared for that": A qualitative assessment of the emotional well-being needs of patients undergoing cystectomy.

Biomarkers of treatment response in bladder cancer.

Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis.

Diagnostic significance of peritumoral enhancement in distinguishing between muscle-invasive and non-muscle-invasive bladder cancer.

An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial.

Modulation of the Tumor Microenvironment in Non-Muscle-Invasive Bladder Cancer by OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: Effects on Tumor-Associated Macrophages, Tumor-Infiltrating Lymphocytes, and Monoamine Oxidases - Beyond the Abstract

Penile & Urethral Cancers

Proposal of a Subclassification of pN3 in Squamous Cell Carcinoma of the Penis.

Human Papillomavirus (HPV) Genotypes in Mixed Squamous Cell Carcinoma of the Penis: A Study of 101 Tumors.

Renal Cancer

Longitudinal Trends of Comorbidities and Survival Among Kidney Cancer Patients in Asian Population.

Spontaneous regression of metastatic clear cell renal cell carcinoma: A report of a rare case and a review of the literature.

Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report.

Associations of physical activity and sedentary time with health-related quality of life in patients with localized renal cell cancer: a cross-sectional analysis within the ReLife study.

Predicting first-line VEGFR-TKI resistance and survival in metastatic clear cell renal cell carcinoma using a clinical-radiomic nomogram.

Systemic therapy for non-clear cell renal cell carcinomas: A systematic review.

Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors.

Primary tumor ablation in metastatic renal cell carcinoma.

Urine leak and vascular complications following robotic partial nephrectomy: a contemporary single-center experience.

Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma.

Prostate Cancer

Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer.

Colibactin Exerts Androgen-dependent and -independent Effects on Prostate Cancer.

A Systematic Review of the Diagnostic Accuracy of Deep Learning Models for the Automatic Detection, Localization, and Characterization of Clinically Significant Prostate Cancer on Magnetic Resonance Imaging.

Small-molecule disruption of androgen receptor-dependent chromatin clusters.

Prostate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: A scoping review and meta-analysis.

Computational analysis of variability and uncertainty in the clinical reference on magnetic resonance imaging radiomics: modelling and performance.

The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer.

Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer.

Association between beta-blocker atenolol use and prostate cancer upgrading in active surveillance.

[225Ac]Ac-PSMA for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.

Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer.

Comparison of online adaptive and non-adaptive magnetic resonance image-guided radiation therapy in prostate cancer using dose accumulation.

Striving for Equity: Examining Health Disparities in Urologic Oncology.

Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer.

St Vincent’s Hospital to Conduct Head-to-Head Trial with Clarity’s SAR-bisPSMA Diagnostic Product

Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings.

Surgical Castration as an Alternative to Improve Systemic Treatment for Advanced Prostate Cancer: A Window of Opportunity for Developing Countries.

HSD3B1, prostate cancer mortality and modifiable outcomes.

Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers.

A Novel Machine Learning-Based Predictive Model of Clinically Significant Prostate Cancer and Online Risk Calculator.

The Role of Nuclear Medicine in Imaging and Therapy of Prostate Cancer: The State of the Art.

Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216.

Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial.

Preclinical and Clinical Evidence for Using Perinatal Tissue Allografts in Nerve Sparing Robot Assisted Radical Prostatectomy to Hasten Recovery of Functional Outcomes: A Literature Review - Beyond the Abstract

Surgery versus radiation for clinically positive nodal prostate cancer in an other cause mortality risk weighted cohort.

Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review.

An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate Cancer.

Study on the Impact of Hormone Therapy for Prostate Cancer on the Quality of Life and the Psycho-Relational Sphere of Patients: ProQoL.

Imaging in Diagnosis and Active Surveillance for Prostate Cancer: A Review.

A pilot randomized clinical trial of a smartphone-based application to support at-home PSA screening and culturally tailored prostate cancer education for African American men: A study protocol.

PRO-P: evaluating the effect of electronic patient-reported outcome measures monitoring compared with standard care in prostate cancer patients undergoing surgery-study protocol for a randomized controlled trial.

Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data - Beyond the Abstract

Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma - Beyond the Abstract

Upper Tract Tumors

Validation of Keratin 17 as a Tissue Biomarker in the Diagnosis of Upper Tract Urothelial Carcinoma.

Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma.

Gold standard nephroureterectomy, chemoprophylaxis and surveillance in upper tract urothelial carcinoma.

Chronic renal impairment predicts oncological outcomes in UTUC patients undergoing RNU.

Testicular Cancer

Oncological microdissection testicular sperm extraction (Onco-microTESE) outcomes for fertility preservation of patients with testicular cancer with azoospermia or severe oligoasthenoteratozoospermia.

Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: A Worldwide Multicenter Study.

Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review.

Late side effects of testicular cancer and treatment: a comprehensive review.

Incidence of Erectile Dysfunction and Testosterone Deficiency in Testicular Cancer Survivors - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC